Cost-effectiveness of prophylaxis with recombinant versus plasma-derived VWF in severe von Willebrand disease in the US

Christina Waldron,Satoko Ito, Daniel Wang,Cecily Allen, Giri Viswanathan,Robert D. Bona,Adam Cuker,George Goshua

Blood（2024）

引用 0|浏览5

暂无评分

摘要

We evaluated the cost-effectiveness of prophylaxis with rVWF versus with pdVWF for patients with severe VWD. We found that rVWF is a cost-saving factor replacement compared to pdVWF across all willingness-to-pay thresholds in the United States.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要